Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BOXR1030
- Development stage
- Phase 2
- Lead developer
- SOTIO Biotech AG
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
BOXR1030 is a next-generation chimeric antigen receptor (CAR) T cell therapy designed to target glypican-3 (GPC3)-expressing solid tumors. It uniquely co-expresses a GPC3-targeted CAR and the exogenous glutamic-oxaloacetic transaminase 2 (GOT2) enzyme, which enhances T cell metabolism and function within the immunosuppressive tumor microenvironment. Preclinical studies have shown that BOXR1030 T cells exhibit improved proliferation, resistance to exhaustion, enhanced cytokine production profiles, and superior antitumor activity compared to standard CAR T cells in models of hepatocellular carcinoma, squamous cell carcinoma of the lung, myxoid/round cell liposarcoma, and Merkel cell carcinoma. The drug is being developed by SOTIO for use in patients with advanced GPC3-positive solid tumors[1][5][6][8].
- Other names
- anti-GPC3-CAR autologous T lymphocytesanti-GPC-3-CAR autologous T lymphocytesanti-GPC 3-CAR autologous T lymphocytesautologous anti-GPC3 CAR T cells BOXR1030
02
Targets
AST (Glutamate oxaloacetate transaminase 1)GPC3 (Glypican-3)
Beyond the preview
Go deeper on BOXR1030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BOXR1030.